Lakefront Biotherapeutics (LKFT) Operating Leases (2019 - 2026)

Lakefront Biotherapeutics (LKFT) has 8 years of Operating Leases data on file, last reported at $5.7 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $5.7 million, down 30.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 30.66% YoY), and the FY2025 annual result was $6.0 million, down 31.47% from the prior year.
• Operating Leases fell to $5.7 million in Q1 2026 per LKFT's latest filing, from $6.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $20.5 million in Q1 2022 and troughed at $4.2 million in Q1 2024.
• A 5-year average of $8.9 million and a median of $8.0 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases plunged 64.51% in 2023, then soared 96.5% in 2025.
• A 5-year view of Operating Leases shows it stood at $15.0 million in 2022, then sank by 64.51% to $5.3 million in 2023, then jumped by 65.59% to $8.8 million in 2024, then tumbled by 31.47% to $6.0 million in 2025, then decreased by 5.92% to $5.7 million in 2026.
• Business Quant data shows LKFT's Operating Leases at $5.7 million in Q1 2026, $6.0 million in Q4 2025, and $6.7 million in Q3 2025.